Ovid Therapeutics (OVID)
(Delayed Data from NSDQ)
$1.17 USD
+0.11 (10.38%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $1.16 -0.01 (-0.85%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Income Statements
Fiscal Year end for Ovid Therapeutics falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 2 | 208 | 13 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 2 | 208 | 13 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 60 | 57 | 84 | 94 | 61 |
Income After Depreciation & Amortization | -59 | -56 | 124 | -81 | -61 |
Non-Operating Income | 7 | 1 | 0 | 0 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -52 | -54 | 124 | -81 | -60 |
Income Taxes | 0 | 0 | 1 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -52 | -54 | 123 | -81 | -60 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -52 | -54 | 123 | -81 | -60 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -58 | -54 | 124 | -81 | -61 |
Depreciation & Amortization (Cash Flow) | 2 | 1 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -59 | -56 | 124 | -81 | -61 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 70.58 | 70.43 | 68.07 | 58.45 | 39.22 |
Diluted EPS Before Non-Recurring Items | -0.74 | -0.77 | 1.76 | -1.39 | -1.54 |
Diluted Net EPS (GAAP) | -0.74 | -0.77 | 1.76 | -1.39 | -1.54 |
Fiscal Year end for Ovid Therapeutics falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.17 | 0.15 | 0.14 | 0.11 | 0.08 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.17 | 0.15 | 0.14 | 0.11 | 0.08 |
SG&A, R&D, and Dept/Amort Expenses | 20.68 | 17.57 | 18.33 | 12.14 | 14.25 |
Income After SG&A, R&D, and Dept/Amort Expenses | -20.51 | -17.42 | -18.19 | -12.03 | -14.17 |
Non-Operating Income | 29.04 | 5.72 | 2.87 | 0.78 | 1.76 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | 8.52 | -11.69 | -15.32 | -11.25 | -12.41 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 8.52 | -11.69 | -15.32 | -11.25 | -12.41 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 8.52 | -11.69 | -15.32 | -11.25 | -12.41 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 71.20 | 70.72 | 70.69 | 70.62 | 70.53 |
Diluted EPS Before Non-Recurring Items | 0.12 | -0.17 | -0.22 | -0.16 | -0.18 |
Diluted Net EPS (GAAP) | 0.12 | -0.17 | -0.21 | -0.16 | -0.18 |